Detalles de la búsqueda
1.
Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma.
Blood
; 139(13): 1939-1953, 2022 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015835
2.
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
Proc Natl Acad Sci U S A
; 118(17)2021 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33883278
3.
High patient satisfaction and increased physical activity following a remote multidisciplinary team multiple myeloma clinic.
Support Care Cancer
; 31(2): 127, 2023 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36680643
4.
The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma.
Haematologica
; 107(3): 721-732, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33596642
5.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33189178
6.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910333
7.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755235
8.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34062004
9.
Proteasome inhibition in multiple myeloma: lessons for other cancers.
Am J Physiol Cell Physiol
; 318(3): C451-C462, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31875696
10.
Differential Regulation of Human Bone Marrow Mesenchymal Stromal Cell Chondrogenesis by Hypoxia Inducible Factor-1α Hydroxylase Inhibitors.
Stem Cells
; 36(9): 1380-1392, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29726060
11.
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
Br J Cancer
; 119(10): 1278-1287, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30318510
12.
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Haematologica
; 103(9): 1422-1432, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30049825
13.
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
Haematologica
; 103(3): 514-521, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29217776
14.
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.
Haematologica
; 103(2): 197-211, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29217780
15.
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.
Haematologica
; 103(11): 1772-1784, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171031
16.
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Am J Hematol
; 97(3): E83-E86, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34882831
17.
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Am J Hematol
; 96(10): E383-E386, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34161627
18.
Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.
Br J Haematol
; 168(1): 14-25, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25296649
19.
Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
Br J Haematol
; 171(4): 453-62, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26213240
20.
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Br J Haematol
; 185(3): 588-592, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30255568